NOVAiCOS Immunotherapeutics

Novaicos is a biotechnology company dedicated to developing innovative oral therapies for patients suffering from metabolic bone diseases. The company's primary focus is on the development of small molecule inhibitors of Schnurri-3 (SHN3), a critical negative regulator of bone formation. By inhibiting SHN3, Novaicos aims to stimulate osteoblast activity and significantly increase bone mineral density, offering a potential breakthrough for conditions like osteoporosis and osteogenesis imperfecta. The company was founded by world-renowned bone biology experts from Harvard Medical School and Massachusetts General Hospital. Currently in the pre-clinical stage, Novaicos is advancing its lead candidates toward clinical trials to provide a more accessible oral alternative to existing injectable anabolic bone therapies.